Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annals of Hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-015-2547-0PMID 26596971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

  2015cited by this paper
• Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

  2014cited by this paper
• Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine

  2014cited by this paper
• Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

  2014cited by this paper
• Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.

  2013cited by this paper
• Monosomal karyotype in MDS: explaining the poor prognosis?

  2013cited by this paper
• Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

  2013cited by this paper
• Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

  2013cited by this paper
• Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

  2013cited by this paper
• A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

  2012cited by this paper
• Revised international prognostic scoring system for myelodysplastic syndromes.

  2012cited by this paper
• Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.

  2012cited by this paper
• Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

  2011cited by this paper
• European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

  2008cited by this paper
• A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  2007cited by this paper
• Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.

  2007cited by this paper
• New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

  2007cited by this paper
• CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

  2007cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

  2005cited by this paper
• Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine

  2001cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

  2000cited by this paper
• Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

  1997cited by this paper

• DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.

  2026cites this paper
• A clinical guide to TP53 mutations in myeloid neoplasms.

  2025cites this paper
• Impact of Decitabine Conditioning on Allo‐HSCT Outcomes in AML and Intermediate‐to‐High‐Risk MDS Patients in Remission

  2025cites this paper
• Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling

  2023cites this paper
• Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.

  2023cites this paper
• Characterizing crosstalk in epigenetic signaling to understand disease physiology.

  2023cites this paper
• Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

  2023cites this paper
• Role of Bcl‐2 inhibition in myelodysplastic syndromes

  2022cites this paper
• DNA Methylation Modulates Aging Process in Adipocytes

  2022cites this paper
• Genome-wide differential DNA methylation analysis of MDA-MB-231 breast cancer cells treated with curcumin derivatives, ST08 and ST09

  2022cites this paper
• Arsenic Dispensing Powder Promotes Erythropoiesis in Myelodysplastic Syndromes via Downregulation of HIF1A and Upregulation of GATA Factors.

  2021cites this paper
• Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia

  2021cites this paper
• The use of hypomethylating agents in hematologic malignancies: treatment preferences and results

  2021cites this paper
• How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML

  2021cites this paper
• Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients

  2021cites this paper
• Advances in epigenetic therapeutics with focus on solid tumors

  2021cites this paper
• Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes

  2021cites this paper
• Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy

  2021cites this paper
• Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

  2021cites this paper
• The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia

  2021cites this paper
• Epigenetic Deregulation of Apoptosis in Cancers

  2021cites this paper
• Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.

  2021cites this paper
• Significance of Enzymes in Modern Healthcare: From Diagnosis to Therapy

  2021cites this paper
• Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine

  2020cites this paper
• Epigenetic Alterations Associated with the Overall Survival and Recurrence Free Survival among Oral Squamous Cell Carcinoma Patients

  2020cites this paper
• Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

  2020cites this paper
• Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials

  2020cites this paper
• Pharmacoepigenetics of Systemic Lupus Erythematosus

  2019cites this paper
• Understanding Cancer Through the Lens of Epigenetic Inheritance, Allele-Specific Gene Expression, and High-Throughput Technology

  2019cites this paper
• DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis

  2019cites this paper
• Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia

  2019cites this paper
• Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

  2019cites this paper
• Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis

  2019cites this paper
• Targeting DNA methylation for treating triple-negative breast cancer

  2019cites this paper
• The Translational Status of Cancer Liquid Biopsies

  2019cites this paper
• Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

  2019cites this paper
• Investigation of epigenetic regulators important for tumour initiation and maintenance

  2019cites this paper
• Novel insights into the effects of manipulating DNA methyltransferase levels on the imprinted and non-imprinted regions of the genome

  2019cites this paper
• Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

  2019cites this paper
• Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

  2019cites this paper
• Can we predict responsiveness to hypomethylating agents in AML?

  2019cites this paper
• Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

  2019cites this paper
• DNA‐modifying Enzymes

  2019cites this paper
• Epigenetics of Aging and Cancer: A Comprehensive Look

  2019cites this paper
• The role of human CBX proteins in human benign and malignant hematopoiesis

  2018cites this paper
• PAN3–PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity.

  2018cites this paper
• Decitabine improves response rate and prolongs progression‐free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO‐016 trial

  2018cites this paper
• Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

  2018cites this paper
• DNA Methylation in Radiation-Induced Carcinogenesis: Experimental Evidence and Clinical Perspectives.

  2018cites this paper
• Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

  2018cites this paper
• Comparison of DNMT1 inhibitors by methylome profiling identifies unique signature of 5-aza-2'deoxycytidine.

  2018cites this paper
• 单倍型造血干细胞移植治疗伴骨髓增生异常综合征相关特征急性髓系白血病临床分析

  2018cites this paper
• Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.

  2018cites this paper
• Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.

  2018cites this paper
• An update on treatment of higher risk myelodysplastic syndromes

  2018cites this paper
• Patterns of mutations in TP53 mutated AML.

  2018cites this paper
• Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype

  2018cites this paper
• Treatment with Hypomethylating Agents (HMA)

  2018cites this paper
• Epigenetic programming, early life nutrition and the risk of metabolic disease.

  2017cites this paper
• Epigenetics and metabolic disease

  2017cites this paper
• Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.

  2017cites this paper
• SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

  2017influential citation
• DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome

  2017cites this paper
• Making the most of hypomethylating agents in myelodysplastic syndromes

  2017cites this paper
• Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

  2017cites this paper
• Myelodysplastic Syndromes: Updates and Nuances.

  2017cites this paper
• Advancing Treatment Approach to the Older Patient with Cancer Through Clinical Trials Participation.

  2017cites this paper
• MYC—Master Regulator of the Cancer Epigenome and Transcriptome

  2017cites this paper
• Innovative strategies for adverse karyotype acute myeloid leukemia

  2017cites this paper
• TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes

  2017cites this paper
• 地西他滨治疗骨髓增生异常综合征及相关肿瘤的疗效预测因素研究

  2017cites this paper
• Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

  2017cites this paper
• No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

  2017cites this paper
• DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.

  2017cites this paper
• How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

  2016cites this paper
• Hypomethylierer Decitabin: Hoffnung für MDS-Patienten mit hohem Risiko?

  2016cites this paper
• TP 53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes

  2016cites this paper
• TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2016cites this paper
• Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

  2016cites this paper
• Targeting the cancer epigenome for therapy

  2016cites this paper
• Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome

  2016cites this paper
• Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases

  2016influential citation
• Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.

  2016cites this paper